Pfizer CentreOne Header Pfizer CentreOne Header

X

Find the latest Drugs in Development and Pipeline Prospector News of Janssen Ortho LLC.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Janssen Ortho LLC
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
State road 933 Km 0 1 Street Statero Gurabo, PR 00778
Telephone
Telephone
+1 787-272-7440
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Idorsia will reacquire the development and commercialization rights for aprocitentan, a potential novel, effective, once-daily, orally active, dual endothelin A and B receptor antagonist and well-tolerated treatment for resistant hypertension, from Janssen.


Lead Product(s): Aprocitentan

Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACT-132577

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Idorsia Pharmaceuticals

Deal Size: $343.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement September 05, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the collaboration, Janssen has chosen a lead gamma-delta T-cell engager bispecific antibody candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings for the treatment of cancer.


Lead Product(s): Bispecific Antibody

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Large molecule

Recipient: Lava Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 01, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Through the collaboration, Janssen enhances its portfolio in B-cell malignancies and strengthens its legacy in hematology, by including C-CAR039 (prizloncabtagene autoleucel), a novel bispecific CAR-T therapy targeting both CD19 and CD20 antigens for the treatment R/R DLBCL.


Lead Product(s): Prizloncabtagene Autoleucel

Therapeutic Area: Oncology Product Name: C-CAR039

Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

Recipient: Cellular Biomedicine Group

Deal Size: $245.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration May 02, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

ESSA will conduct a Phase 1 trial evaluating the safety, pharmacokinetics, drug-drug interactions, and preliminary anti-tumor activity of EPI-7386 when administered in combination with either apalutamide or abiraterone acetate plus prednisone in patients with prostate cancer.


Lead Product(s): Masofaniten,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Product Name: EPI-7386

Highest Development Status: Phase IProduct Type: Small molecule

Recipient: Essa Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement April 12, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The disappointed outcome of the confirmatory trials leads to voluntarily withdraw, in the U.S., accelerated IMBRUVICA® (ibrutinib) approvals for patients with the blood cancers mantle cell lymphoma who have received at least one prior therapy and with marginal zone lymphoma.


Lead Product(s): Ibrutinib,Bendamustine

Therapeutic Area: Oncology Product Name: Imbruvica

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: AbbVie Inc

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 06, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Janssen will use Biocytogen’s proprietary RenLite® platform to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications.


Lead Product(s): Antibody

Therapeutic Area: Technology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Large molecule

Recipient: Biocytogen

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 08, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

JNJ-2113 (formerly known as PN-235) is the first-and only-in-class oral IL-23 receptor antagonist as a potential oral targeted therapy for plaque psoriasis.


Lead Product(s): PN-235

Therapeutic Area: Dermatology Product Name: JNJ-2113

Highest Development Status: Phase IIProduct Type: Peptide

Recipient: Protagonist Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 07, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

ACT-132577 (aprocitentan) is a dual endothelin receptor antagonist, which potently inhibits the binding of ET-1 to ETA and ETB receptors. It has a mechanism of action that is ideally suited for the pathophysiology of resistant hypertension.


Lead Product(s): Aprocitentan

Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACT-132577

Highest Development Status: Phase IIIProduct Type: Small molecule

Recipient: Idorsia Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 31, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The license agreement terms for Janssen Biotech, Inc. to develop, manufacture and market DARZALEX under the exclusive worldwide license.


Lead Product(s): Daratumumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: ApprovedProduct Type: Large molecule

Recipient: Genmab

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 22, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY